Table 3. Anti-epileptic drug regimens at the time of recurrence or end of follow-up.
| Total (n = 104) | Recurrent PSS (n = 31) | No Recurrence(n = 73) | p value* | |
|---|---|---|---|---|
| AEDs use, n (%) | ||||
| VPA monotherapy | 23 (22.1) | 11 (35.5) | 12 (16.4) | 0.032 |
| CBZ monotherapy | 15 (14.4) | 2 (6.5) | 13 (17.8) | 0.13 |
| PHT monotherapy | 22 (21.2) | 4 (12.9) | 18 (24.7) | 0.18 |
| Other AED monotherapies † | 10 (9.6) | 2 (6.5) | 8 (11.0) | 0.48 |
| Polytherapy | 20 (19.2) | 10 (32.3) | 10 (13.7) | 0.028 |
| None or discontinuation | 14 (13.5) | 2 (6.45) | 12 (16.4) | 0.17 |
Data are expressed as median (IQR: interquartile range) or number of patients (%: percentages). Abbreviations: AEDs, antiepileptic drugs; PSS, post stroke seizures; VPA, valproic acid; CBZ, carbamazepine; PHT, phenytoin.
* The Mann—Whitney U test was used to compare AED regimens between recurrent PSS and no recurrent groups.
†Other AED monotherapies: 3 patients were taking zonisamide and 7 patients were taking levetiracetam.